Observations placeholder
Potiga
Identifier
019852
Type of Spiritual Experience
Background
A description of the experience
Retigabine (INN) or ezogabine (USAN), codenamed D-23129, is an anticonvulsant used as an adjunctive treatment for partial epilepsies in treatment-experienced adult patients. It was approved by the European Medicines Agency under the trade name Trobalt on March 28, 2011, and by the United States Food and Drug Administration (FDA), under the trade name Potiga, on June 10, 2011.
Retigabine works primarily as a potassium channel opener—that is, by activating a certain family of voltage-gated potassium channels in the brain. This mechanism of action is unique among antiepileptic drugs, and is being considered for the treatment of other neurologic conditions, including migraine, tinnitus and neuropathic pain.
Adverse effects
The adverse effects found in the Phase II trial mainly affected the central nervous system, and appeared to be dose-related. The most common adverse effects were drowsiness, dizziness and vertigo, confusion, and slurred speech. Less common side effects included tremor, memory loss, gait disturbances, and double vision. In 2013 FDA warned the public that, Potiga (ezogabine) can cause blue skin discoloration and eye abnormalities characterized by pigment changes in the retina. FDA does not currently know if these changes are reversible. FDA is working with the manufacturer to gather and evaluate all available information to better understand these events. FDA will update the public when more information is available Psychiatric symptoms and difficulty urinating have also been reported, with most cases occurring in the first 2 months of treatment.
On Dec, 31, 2016 353 people reported to have side effects when taking Potiga.
Among them, 6 people (1.7%) have Hallucination
Time on Potiga when people have Hallucination :
< 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
Hallucination | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Gender of people who have Hallucination when taking Potiga :
Female | Male | |
Hallucination | 100.00% | 0.00% |
Age of people who have Hallucination when taking Potiga :
0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
Hallucination | 0.00% | 0.00% | 66.67% | 0.00% | 0.00% | 33.33% | 0.00% | 0.00% |